NEUCA S.A. Stock

Equities

NEU

PLTRFRM00018

Pharmaceuticals

Market Closed - Warsaw S.E. 11:55:56 2024-06-06 am EDT 5-day change 1st Jan Change
937 PLN -0.53% Intraday chart for NEUCA S.A. +2.74% +1.30%
Sales 2024 * 12.97B 3.29B Sales 2025 * 13.68B 3.47B Capitalization 4.21B 1.07B
Net income 2024 * 194M 49.19M Net income 2025 * 247M 62.63M EV / Sales 2024 * 0.35 x
Net Debt 2024 * 305M 77.33M Net Debt 2025 * 163M 41.28M EV / Sales 2025 * 0.32 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 4,633
Yield 2024 *
1.59%
Yield 2025 *
2.12%
Free-Float 35.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.43%
1 week+3.29%
Current month+3.29%
1 month+2.50%
3 months+6.32%
6 months+12.54%
Current year+1.84%
More quotes
1 week
896.00
Extreme 896
946.00
1 month
896.00
Extreme 896
969.00
Current year
790.00
Extreme 790
969.00
1 year
630.00
Extreme 630
969.00
3 years
527.00
Extreme 527
969.00
5 years
279.00
Extreme 279
969.00
10 years
182.10
Extreme 182.1
969.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 00-12-31
Founder - 89-12-31
Director of Finance/CFO - 10-07-31
Members of the board TitleAgeSince
Founder - 89-12-31
Director/Board Member 72 09-06-15
Founder - 89-12-31
More insiders
Date Price Change Volume
24-06-06 937 -0.53% 156
24-06-05 942 +4.43% 4,429
24-06-04 902 -0.77% 618
24-06-03 909 -0.33% 425
24-05-31 912 0.00% 339

Delayed Quote Warsaw S.E., June 05, 2024 at 11:55 am EDT

More quotes
Neuca SA is a Poland-based company, which operates in the healthcare market. The Company is mainly involved in the distribution of drugs to pharmacies. It also operates in other sectors of the health market, such as production of drugs, supplements and cosmetics under its own brand, clinical trials, telemedicine, Information Technology (IT) solutions and e-commerce in the health care industry.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
942 PLN
Average target price
1,012 PLN
Spread / Average Target
+7.47%
Consensus

Quarterly revenue - Rate of surprise